{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:09Z","timestamp":1790612109129,"version":"4.1.0"},"reference-count":7,"publisher":"SMC Media","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Dasatanib is a second-generation tyrosine kinase inhibitor with activity on the BCR-ABL fusion gene. it is used in the treatment of BCR-ABL positive chronic myeloid leukaemia and has the known side effect of pleural effusion. This usually involves exudate with the presence of lymphocytes. A more common side effect is the development of chylothorax. We describe a case of a 67-years-old man with chronic myeloid leukaemia, for which treatment with dasatinib, with the presence of a right-sided chylothorax. The man presented at an outpatient consultation due to complaints for exertional dyspnoea. Radiographic imaging showed the presence of right-sided pleural effusion. Several punctures were performed with an evacuation of 4,900 mL bloody chylous fluid in total.\u00a0Each puncture revealed an increased concentration of triglycerides on the fluid, hence confirming a recurring chylothorax.\u00a0A pleurodesis was performed as a final therapy. Bosutinib was substituted for dasatinib eight months prior to initial admission, making this the first reported persisting dasatinib-induced chylothorax after discontinuation.\u00a0<\/jats:p>","DOI":"10.12890\/2022_003601","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T03:21:06Z","timestamp":1666063266000},"source":"Crossref","is-referenced-by-count":6,"title":["A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib"],"prefix":"10.12890","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-0331","authenticated-orcid":false,"given":"Nicolas","family":"Bradt","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, AZ Glorieux, Ronse, Belgium; Department of Internal Medicine, UZ Gent, Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8299-9230","authenticated-orcid":false,"given":"Frederic","family":"Olbrechts","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, AZ Glorieux, Ronse, Belgium; Department of Internal Medicine, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5390-8704","authenticated-orcid":false,"given":"Patrick","family":"Alexander","sequence":"first","affiliation":[{"name":"Department of Pneumology, AZ Glorieux, Ronse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-9352","authenticated-orcid":false,"given":"Alexander","family":"Salembier","sequence":"first","affiliation":[{"name":"Department of Haematology, AZ Glorieux, Ronse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10397","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"10.12890\/2022_003601_ref1","doi-asserted-by":"crossref","unstructured":"<li>Brixey AG, Light RW. Pleural effusions due to dasatinib. <em>Curr Opin Pulm Med.<\/em> 2010;<strong>16<\/strong>(4):351\u20136. <\/li>","DOI":"10.1097\/MCP.0b013e328338c486"},{"key":"10.12890\/2022_003601_ref2","doi-asserted-by":"crossref","unstructured":"<li>Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial. <em>J Clin Oncol<\/em> 2016;<strong>34<\/strong>(20):2333\u201340. <\/li>","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"10.12890\/2022_003601_ref3","doi-asserted-by":"crossref","unstructured":"<li>Hsu CC, Hsu JF, Wu KL. Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review. <em>Respirol Case Rep<\/em>. 2021;<strong>9<\/strong>(6):1\u20135. <\/li>","DOI":"10.1002\/rcr2.753"},{"key":"10.12890\/2022_003601_ref4","doi-asserted-by":"crossref","unstructured":"<li>Chen B, Wu Z, Wang Q, Li W, Cheng D. Dasatinib-induced chylothorax: report of a case and review of the literature. <em>Invest New Drugs.<\/em> 2020;<strong>38<\/strong>(5):1627\u201332. <\/li>","DOI":"10.1007\/s10637-020-00932-3"},{"key":"10.12890\/2022_003601_ref5","doi-asserted-by":"crossref","unstructured":"<li>Al-abcha A, Iftikhar MH, Rous FA, Laird-Fick H. Chylothorax: Complication attributed to dasatinib use. <em>BMJ Case Rep.<\/em> 2019;<strong>12<\/strong>(12):10\u20132. <\/li>","DOI":"10.1136\/bcr-2019-231653"},{"key":"10.12890\/2022_003601_ref6","doi-asserted-by":"crossref","unstructured":"<li>Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH. Etiology of chylothorax in 203 patients. <em>Mayo Clin Proc.<\/em> 2005 Jul;<strong>80<\/strong>(7):867-70. doi: 10.4065\/80.7.867. PMID: 16007891.<\/li>","DOI":"10.4065\/80.7.867"},{"key":"10.12890\/2022_003601_ref7","doi-asserted-by":"crossref","unstructured":"<li>Phan C, Jutant E-M, Tu L, Thuillet R, Seferian A, Montani D, et al. Dasatinib increases endothelial permeability leading to pleural effusion. <em>Eur Respir J.<\/em> 2018;<strong>51<\/strong>(1):1\u201314. <\/li>","DOI":"10.1183\/13993003.01096-2017"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3601\/3260","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3601\/3261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3601\/3261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T13:55:37Z","timestamp":1755784537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/3601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":7,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.12890\/2022_003601","relation":{"has-manifestation":[{"id-type":"other","id":"1-91-3601-g3260","asserted-by":"subject"},{"id-type":"other","id":"1-91-3601-g3261","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-91","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"value":"2284-2594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]}}}